Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
1999-6-14
pubmed:abstractText
Fanconi anemia (FA) is an autosomal recessive cancer susceptibility syndrome with at least eight complementation groups (A-H). Three FA genes, corresponding to complementation groups A, C, and G, have been cloned, but the function of the encoded FA proteins remains unknown. We recently demonstrated that the FANCA and FANCC proteins bind and form a nuclear complex. In the current study, we identified a homozygous mutation in the FANCA gene (3329A>C) in an Egyptian FA patient from a consanguineous family. This mutant FANCA allele is predicted to encode a mutant FANCA protein, FANCA(H1110P), in which histidine 1110 is changed to proline. Initially, we characterized the FANCA(H1110P) protein, expressed in an Epstein Barr virus (EBV)-immortalized lymphoblast line derived from the patient. Unlike wild-type FANCA protein expressed in normal lymphoblasts, FANCA(H1110P) was not phosphorylated and failed to bind to FANCC. To test directly the effect of this mutation on FANCA function, we used retroviral-mediated transduction to express either wild-type FANCA or FANCA(H1110P) protein in the FA-A fibroblast line, GM6914. Unlike wild-type FANCA, the mutant protein failed to complement the mitomycin C sensitivity of these cells. In addition, the FANCA(H1110P) protein was defective in nuclear accumulation in the transduced cells. The characteristics of this mutant protein underscore the importance of FANCA phosphorylation, FANCA/FANCC binding, and nuclear accumulation in the function of the FA pathway.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0301-472X
pubmed:author
pubmed:issnType
Print
pubmed:volume
27
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
587-93
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed-meshheading:10210316-Amino Acid Substitution, pubmed-meshheading:10210316-Cell Cycle Proteins, pubmed-meshheading:10210316-Cell Line, pubmed-meshheading:10210316-Cell Nucleus, pubmed-meshheading:10210316-DNA Mutational Analysis, pubmed-meshheading:10210316-DNA-Binding Proteins, pubmed-meshheading:10210316-Fanconi Anemia, pubmed-meshheading:10210316-Fanconi Anemia Complementation Group C Protein, pubmed-meshheading:10210316-Fanconi Anemia Complementation Group Proteins, pubmed-meshheading:10210316-Gene Expression, pubmed-meshheading:10210316-Genetic Complementation Test, pubmed-meshheading:10210316-Humans, pubmed-meshheading:10210316-Immunoblotting, pubmed-meshheading:10210316-Lymphocytes, pubmed-meshheading:10210316-Nuclear Proteins, pubmed-meshheading:10210316-Phosphorylation, pubmed-meshheading:10210316-Point Mutation, pubmed-meshheading:10210316-Protein Biosynthesis, pubmed-meshheading:10210316-Proteins, pubmed-meshheading:10210316-Reverse Transcriptase Polymerase Chain Reaction, pubmed-meshheading:10210316-Transfection
pubmed:year
1999
pubmed:articleTitle
A patient-derived mutant form of the Fanconi anemia protein, FANCA, is defective in nuclear accumulation.
pubmed:affiliation
Dana-Farber Cancer Institute, and Department of Pediatrics, Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S.